

# Michael Grynberg

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7922682/publications.pdf>

Version: 2024-02-01

53  
papers

1,484  
citations

331670

21  
h-index

345221

36  
g-index

62  
all docs

62  
docs citations

62  
times ranked

1207  
citing authors

#	ARTICLE	IF	CITATIONS
1	ESHRE guideline: ovarian stimulation for IVF/ICSI. Human Reproduction Open, 2020, 2020, hoaa009.	5.4	205
2	Serum anti-Mullerian hormone levels are negatively related to Follicular Output RaTe (FORT) in normo-cycling women undergoing controlled ovarian hyperstimulation. Human Reproduction, 2011, 26, 671-677.	0.9	94
3	Serum progesterone concentration and live birth rate in frozen-thawed embryo transfers with hormonally prepared endometrium. Reproductive BioMedicine Online, 2019, 38, 472-480.	2.4	91
4	Perspectives on the development and future of oocyte IVM in clinical practice. Journal of Assisted Reproduction and Genetics, 2021, 38, 1265-1280.	2.5	82
5	Antral follicle responsiveness to follicle-stimulating hormone administration assessed by the Follicular Output RaTe (FORT) may predict in vitro fertilization-embryo transfer outcome. Human Reproduction, 2012, 27, 1066-1072.	0.9	80
6	Fertility preservation in Turner syndrome. Fertility and Sterility, 2016, 105, 13-19.	1.0	77
7	Similar in vitro maturation rates of oocytes retrieved during the follicular or luteal phase offer flexible options for urgent fertility preservation in breast cancer patients. Human Reproduction, 2016, 31, 623-629.	0.9	74
8	Ovarian tissue and follicle transplantation as an option for fertility preservation. Fertility and Sterility, 2012, 97, 1260-1268.	1.0	71
9	Anti-Mullerian Hormone: More than a biomarker of female reproductive function. Journal of Gynecology Obstetrics and Human Reproduction, 2019, 48, 19-24.	1.3	51
10	In vitro maturation of oocytes: uncommon indications. Fertility and Sterility, 2013, 99, 1182-1188.	1.0	47
11	What threshold values of antral follicle count and serum AMH levels should be considered for oocyte cryopreservation after in vitro maturation?. Human Reproduction, 2016, 31, 1493-1500.	0.9	44
12	New trends in female fertility preservation: in vitro maturation of oocytes. Future Oncology, 2012, 8, 1567-1573.	2.4	42
13	First Birth Achieved After In Vitro Maturation of Oocytes From a Woman Endowed With Multiple Antral Follicles Unresponsive to Follicle-stimulating Hormone. Journal of Clinical Endocrinology and Metabolism, 2013, 98, 4493-4498.	3.6	38
14	Serum anti-Mullerian hormone is associated with the number of oocytes matured in vitro and with primordial follicle density in candidates for fertility preservation. Fertility and Sterility, 2019, 111, 357-362.	1.0	34
15	Oocyte vitrification for preserving fertility in patients with endometriosis: first observational cohort study and many unresolved questions. Letter to the Editor. European Journal of Obstetrics, Gynecology and Reproductive Biology, 2018, 220, 140-141.	1.1	32
16	BRCA1/2 gene mutations do not affect the capacity of oocytes from breast cancer candidates for fertility preservation to mature in vitro. Human Reproduction, 2019, 34, 374-379.	0.9	31
17	Understanding Follicular Output Rate (FORT) and its Implications for POSEIDON Criteria. Frontiers in Endocrinology, 2019, 10, 246.	3.5	28
18	Should we consider day-2 and day-3 embryo morphology before day-5 transfer when blastocysts reach a similar good quality?. Reproductive BioMedicine Online, 2017, 35, 521-528.	2.4	27

#	ARTICLE	IF	CITATIONS
19	First birth achieved after fertility preservation using vitrification of in vitro matured oocytes in a woman with breast cancer. <i>Annals of Oncology</i> , 2020, 31, 541-542.	1.2	27
20	Age as A Predictor of Embryo Quality Regardless of The Quantitative Ovarian Response. <i>International Journal of Fertility &amp; Sterility</i> , 2017, 11, 40-46.	0.2	23
21	Are age and anti-Müllerian hormone good predictors of ovarian reserve and response in women undergoing IVF?. <i>Jornal Brasileiro De Reproducao Assistida</i> , 2018, 22, 215-220.	0.7	23
22	Oncologic results of fertility sparing surgery of cervical cancer: An updated systematic review. <i>Gynecologic Oncology</i> , 2022, 165, 169-183.	1.4	21
23	Anti-Müllerian Hormone in Fertility Preservation: Clinical and Therapeutic Applications. <i>Clinical Medicine Insights Reproductive Health</i> , 2019, 13, 117955811985475.	3.9	20
24	Live birth rate after use of cryopreserved oocytes or embryos at the time of cancer diagnosis in female survivors: a retrospective study of ten years of experience. <i>Journal of Assisted Reproduction and Genetics</i> , 2021, 38, 1767-1775.	2.5	15
25	Use of the EFI score in endometriosis-associated infertility: A cost-effectiveness study. <i>European Journal of Obstetrics, Gynecology and Reproductive Biology</i> , 2020, 253, 296-303.	1.1	14
26	Is it acceptable to destroy or include human embryos before day 5 in research programmes?. <i>Reproductive BioMedicine Online</i> , 2014, 28, 522-529.	2.4	13
27	Does the prognosis after PGT for structural rearrangement differ between female and male translocation carriers?. <i>Reproductive BioMedicine Online</i> , 2020, 40, 684-692.	2.4	13
28	Antral follicle responsiveness to FSH, assessed by the follicular output rate (FORT), is altered in Hodgkin's lymphoma when compared with breast cancer candidates for fertility preservation. <i>Journal of Assisted Reproduction and Genetics</i> , 2018, 35, 91-97.	2.5	12
29	In vitro maturation of oocytes for preserving fertility in autoimmune premature ovarian insufficiency. <i>Fertility and Sterility</i> , 2020, 114, 848-853.	1.0	12
30	First follow-up of art pregnancies in the context of the COVID-19 outbreak. <i>European Journal of Obstetrics, Gynecology and Reproductive Biology</i> , 2020, 253, 71-75.	1.1	10
31	The past, present and future of fertility preservation in cancer patients. <i>Future Oncology</i> , 2015, 11, 2667-2680.	2.4	9
32	A comparison of the effects of three luteal phase support protocols with estrogen on in vitro fertilization-embryo transfer outcomes in patients on a GnRH antagonist protocol. <i>Jornal Brasileiro De Reproducao Assistida</i> , 2019, 23, 239-245.	0.7	9
33	Comparison of GnRH agonist and hCG for priming in vitro maturation cycles in cancer patients undergoing urgent fertility preservation. <i>PLoS ONE</i> , 2018, 13, e0208576.	2.5	8
34	A cost-effectiveness analysis comparing the originator follitropin alfa to its biosimilars in patients undergoing a medically assisted reproduction program from a French perspective. <i>Journal of Medical Economics</i> , 2019, 22, 108-115.	2.1	7
35	Double in vitro maturation increases the number of vitrified oocytes available for fertility preservation when ovarian stimulation is unfeasible. <i>Scientific Reports</i> , 2020, 10, 18555.	3.3	6
36	Priming Before In Vitro Maturation Cycles in Cancer Patients Undergoing Urgent Fertility Preservation: a Randomized Controlled Study. <i>Reproductive Sciences</i> , 2020, 27, 2247-2256.	2.5	6

#	ARTICLE	IF	CITATIONS
37	Cryopreservation of small numbers of human spermatozoa in a Stripper tip: Report of the first live-birth worldwide. <i>Cryobiology</i> , 2021, 99, 103-105.	0.7	6
38	Early follicle development alters the relationship between antral follicle counts and inhibin B and follicle-stimulating hormone levels on cycle day 3. <i>Fertility and Sterility</i> , 2010, 93, 894-899.	1.0	5
39	Fertility preservation: should we reconsider the terminology?. <i>Human Reproduction</i> , 2019, 34, 1855-1857.	0.9	5
40	National survey on the opinions of French specialists in assisted reproductive technologies about social issues impacting the future revision of the French Bioethics laws. <i>Journal of Gynecology Obstetrics and Human Reproduction</i> , 2020, 49, 101902.	1.3	5
41	Live birth after in-vitro maturation of oocytes in a patient with specific ovarian insufficiency caused by long-term mitotane treatment for adrenocortical carcinoma. <i>Reproductive BioMedicine Online</i> , 2022, 44, 304-309.	2.4	5
42	Early follicle development during the luteal-follicular transition affects the predictability of serum follicle-stimulating hormone but not antimüllerian hormone levels on cycle day 3. <i>Fertility and Sterility</i> , 2010, 94, 1827-1831.	1.0	4
43	Medical techniques of fertility preservation in the male and female. <i>Journal of Visceral Surgery</i> , 2018, 155, S3-S9.	0.8	4
44	In vitro maturation is a viable option for urgent fertility preservation in young women with hematological conditions. <i>Hematological Oncology</i> , 2020, 38, 560-564.	1.7	4
45	What is the threshold of mature oocytes to obtain at least one healthy transferable cleavage-stage embryo after preimplantation genetic testing for fragile X syndrome?. <i>Human Reproduction</i> , 2021, 36, 3003-3013.	0.9	4
46	Women utilizing oocyte donation have a decreased live birth rate if they displayed a low progesterone level in a previous hormonal replacement mock cycle. <i>Journal of Assisted Reproduction and Genetics</i> , 2021, 38, 605-612.	2.5	3
47	Could hormonal and follicular rearrangements explain timely menopause in unilaterally oophorectomized women?. <i>Human Reproduction</i> , 2021, 36, 1941-1947.	0.9	3
48	Influence of breast cancer prognostic factors on oocyte <i>in vitro</i> maturation outcomes performed for urgent fertility preservation. <i>Human Reproduction</i> , 2022, 37, 1480-1488.	0.9	3
49	Letter in reply to "Fertility preservation before an ABVD protocol: no new evidence to support changing the recommendations". <i>Future Oncology</i> , 2017, 13, 591-592.	2.4	1
50	Preservación de la fertilidad femenina. <i>EMC - Ginecología-Obstetricia</i> , 2017, 53, 1-15.	0.0	1
51	Fertility Preservation in Women. , 2019, , 603-614.		0
52	Factors Associated With the Discussion of Fertility Preservation in a Cohort of 1,357 Young Breast Cancer Patients Receiving Chemotherapy. <i>Frontiers in Oncology</i> , 2021, 11, 701620.	2.8	0
53	Fertility of tomorrow: Are there any restrictions left?. <i>Annales D'Endocrinologie</i> , 2022, , .	1.4	0